The U.S. Centers for Medicare & Medicaid Services on Tuesday identified several Pfizer-branded therapies for the third cycle of its Drug Price Negotiation Program, marking the first time Medicare Part B–reimbursed medicines are included. Among the 15 total drugs named, two oncology and one autoimmune treatment from Pfizer will enter price talks, exposing anticipated annual Part B spending of approximately $2.3 billion to negotiation. Investors should note that negotiated price adjustments, slated to take effect in 2026, could reduce reimbursement rates by up to 25%, potentially trimming Pfizer’s Part B revenue by an estimated $200 million to $300 million annually.

Analysts project Pfizer’s fourth-quarter core earnings per share to decline by roughly 5% compared with the year-ago period, driven by waning COVID-19 vaccine and antiviral sales and increased R&D investments in late-stage oncology programs. Consensus revenue estimates stand near $14 billion, reflecting low–single-digit growth as legacy product sales partially offset pandemic product roll-offs. Operating expenses are expected to rise about 7%, fueled by expanded clinical trial activity and elevated manufacturing costs, leaving limited room for an upside surprise when the full report arrives in late February.

Over the past six months, Pfizer’s total shareholder return trailed Merck and Johnson & Johnson by approximately eight percentage points, as market concerns mounted over an impending 2026 patent cliff that could expose up to $10 billion in annual sales to generic competition. Merck’s immuno-oncology lineup and J&J’s diversified medical devices portfolio have outpaced Pfizer’s reliance on pandemic‐era products, prompting several sell-side firms to lower their 12-month target prices. Meanwhile, management’s guidance for mid-single-digit revenue growth next year has been described as lukewarm, reinforcing a cautious stance among institutional holders.

Despite headline regulatory risks from the proposed Great Healthcare Plan, Pfizer secured a three-year carve-out from Section 232 global price parity requirements, insulating roughly $18 billion in annual U.S. pharma sales from immediate tariff exposure. In addition, anticipated changes to the pharmacy benefit manager rebate structure could bolster gross margins by up to 150 basis points by 2027. Management has highlighted the launch of TrumpRx.gov as a volume catalyst rather than a revenue headwind, forecasting incremental patient access that could drive mid‐single-digit growth in core volumes even if average selling prices moderate.